#China #Beijing #Synthetic Biology #Tsingke Biotech #iGeneTech

Tsingke Biotech and iGeneTech Join Forces to Transform Synthetic Biology

In a significant advancement for the field of biotechnology, Beijing Tsingke Biotech Co., Ltd. and iGeneTech Bioscience Co., Ltd. have established a strategic partnership aimed at revolutionizing synthetic biology. The collaboration, which was formalized during a signing ceremony at Tsingke Biotech’s headquarters in Beijing, marks a crucial step toward enhancing product development and expanding market access in this rapidly evolving sector.

Harnessing Combined Expertise

Both companies bring unique strengths that make this partnership a promising venture. Tsingke Biotech, renowned for its expertise in gene synthesis, offers a comprehensive industrial chain encompassing everything from raw materials to cutting-edge digital technologies. Their innovative approach includes high-throughput synthesis and a sophisticated production system, capable of scaling up from laboratory outputs to industrial-scale synthesis. The company’s offerings include:

• - Primer Synthesis (<300nt)
• - Gene Synthesis (300bp–5kb)
• - Long Gene Synthesis (>5kb)

Meanwhile, iGeneTech contributes its advanced Ignite 3.0 high-throughput synthesis platform. This proprietary tool is capable of processing oligo pools ranging from 4,000 to an impressive 650,000 in size, delivering synthesis lengths of up to 200 nucleotides with an incredibly low error rate of 0.2%. This technological capability is set to address challenges related to speed and cost-effectiveness in gene synthesis.

A Vision for Innovation and Sustainability

The CEOs of both companies expressed enthusiasm for the new collaboration. Mr. Shijin Ma, CEO of Tsingke Biotech, stated, "We are excited to partner with iGeneTech, whose expertise enhances our strengths in gene synthesis. This partnership will accelerate the translation of technological innovations into real-world applications, driving the industry forward."

Similarly, Mr. Wanshi Cai, CEO of iGeneTech, remarked, "Tsingke Biotech's robust industrial chain and leadership in gene synthesis will be pivotal for our growth. Together, we aim to push the boundaries of synthetic biology across different sectors."

The common goal is to create an integrated system that covers the entire spectrum from synthesis to application, focusing on innovation, sustainability, and precision. This integrated approach reflects the pressing demands of a swiftly shifting market landscape, positioning both companies as leaders in synthetic biology.

About the Partners

Tsingke Biotech is a pioneering player in synthetic biology, recognized for its mission to construct "the world's greatest gene factory." By merging proprietary reagents, consumables, and synthesis technology with AI-driven biological manufacturing, Tsingke Biotech delivers high-quality gene synthesis services. Its applications extend across various industries, including biopharmaceuticals, agriculture, food production, and environmental science.

iGeneTech, on the other hand, specializes in gene capture technologies, holding significant intellectual property in areas such as next-generation sequencing (NGS) probe hybridization and multiplex PCR. The company’s abilities in high-quality oligo pool synthesis equip it to produce precise and uniform sgRNA libraries for gene editing applications, further emphasizing the partnership’s potential in pioneering research and development in this field.

Conclusion

As the synthetic biology field continues to grow and evolve, the alliance between Tsingke Biotech and iGeneTech signals a promising future. Their combined expertise and shared vision position them at the forefront of biotechnological innovation, ready to deliver significant advancements that could transform industries for years to come.